

# Genus plc

08:30 11 Sep 2019

## Genus confirms sexing semen technology infringed three patents

A US court has found that Genus plc's (LON:GNS) sexing semen technology infringed three patents asserted by Inguran, LLC and Cytonome/ST.

The technology, which competes with ST in the market for processing sexed bovine semen, was being sold by ABS Global Inc under the IntelliGen brand.

A jury at the US District Court for the Western District of Wisconsin ruled that ABS will have to pay a royalty of US\$2.60 for each straw of sexed semen produced in the US that were part of the three infringed patents.

ABS has now modified the IntelliGen technology to avoid continued infringement.

The litigation forms part of a long-running dispute between ABS Global Inc, Inguran, and Cytonome over the development and launch of Genus' sexed semen technology.

In 2014, a court ruled that Inguran and Cytonome willfully maintained an illegal monopoly in the US market for sexed bovine semen processing. The court found that ABS had infringed a patent and this was sent back for a retrial.

Inguran, and Cytonome filed patent infringement claims against Genus and ABS Global in 2017, claiming ABS's technology infringed upon seven patents. Ahead of the second trial, ABS successfully demonstrated non-infringement of five of the seven patents and dismissed the trade secret and breach of contract claims.

"IntelliGen provides farmers and bull studs with a novel technology for sexing bovine semen that focuses on fertility outcomes and has seen a rapid uptake since its launch in 2017," Genus said.

"ABS will continue to expand and commercialise its IntelliGen technology providing customers and third party bull studs with an alternative service provider, increased competition and improved fertility outcomes."

**Price:** 3160

**Market Cap:** £2.06 billion

### 1 Year Share Price Graph



### Share Information

**Code:** GNS

**Listing:** LSE

**52 week High Low**  
3709.98 2158

**Sector:** Pharma & Biotech

**Website:** [www.genusplc.com](http://www.genusplc.com)

### Company Synopsis:

*Genus' principal activity is the global application of quantitative genetics and biotechnology to animal breeding. The Company operates in five operating segments: North America, Latin America, Europe, Far East, and research and development. The research and development segment includes research, bovine product development and porcine product development.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is

provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.